Avapritinib: First Approval
Sign Up to like & getrecommendations! Published in 2020 at "Drugs"
DOI: 10.1007/s40265-020-01275-2
Abstract: Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal… read more here.
Keywords: avapritinib; first approval; treatment; avapritinib first ... See more keywords
Palpable purpuric eruption mimicking vasculitis following avapritinib
Sign Up to like & getrecommendations! Published in 2022 at "JAAD Case Reports"
DOI: 10.1016/j.jdcr.2022.01.031
Abstract: CAE: cutaneous adverse events GIST: gastrointestinal stromal tumor KIT: tyrosine-protein kinase KIT/CD117 LCV: leukocytoclastic vasculitis PDGFRA: platelet-derived growth factor receptor alpha TK: tyrosine kinase TKI: tyrosine kinase inhibitor INTRODUCTION Tyrosine kinase (TK) inhibitors (TKI) are… read more here.
Keywords: vasculitis; palpable purpuric; tyrosine; avapritinib ... See more keywords